scholarly journals Bullous Pemphigoid an Autoimmune Skin Disease: A Case Report

2020 ◽  
Vol 65 (1) ◽  
pp. 161-163
Author(s):  
Maheshwari V ◽  
Tasneem Abdul Gafoor ◽  
Ajeena Anto ◽  
Syam Prakash KR ◽  
Shahina KP ◽  
...  
Keyword(s):  
Case Report ◽  
Bullous Pemphigoid ◽  
Skin Disease

scholarly journals BULLOUS PEMPHIGOID A RARE AUTOIMMUNE DISEASE: A CASE REPORT

2019 ◽  
Vol 4 (2) ◽  
pp. 20-23
Author(s):  
S. M. Biradar ◽  
S. Dhanavidya ◽  
P. Kavya ◽  
T. Keerthi ◽  
N. Sunanda ◽  
...  
Keyword(s):  
Case Report ◽  
Bullous Pemphigoid ◽  
Male Patient ◽  
Skin Disease ◽  
The Elderly ◽  
Skin Lesions ◽  
Treatment Modalities ◽  
Susceptibility To Infection ◽  
Electrolyte Disturbances ◽  
Upper And Lower Extremities

Background. Bullous pemphigoid (BP) is a rare autoimmune blistering skin disease in the elderly and it is manifested by cutaneous blisters on the skin lesions. The objective was to emphasize the rare case of BP. Methods. A case report of BP in a 58-year-old male patient admitted to a dermatology ward is presented. Results. A 58-year-old male patient with complaints of fluid-filled skin lesions, was examined initially over the trunk, gradually progressed involving B/L upper and lower extremities. Even though the patient was treated with the recommended therapy of corticosteroid (Dexamethasone) along with adjuvant drugs, new skin lesions continued to develop, and the patient’s condition worsened. The Prednisolone was started in place of Dexamethasone on the fifth day of treatment at its higher dose (50mg/day), the Prednisolone proved its efficacy to combat the extensive condition of BP. Conclusions. Bullous pemphigoid is a distressing blistering skin disease. Untreated disease is often fatal because of the susceptibility to infection and fluid-electrolyte disturbances. The mortality of patients with bullous pemphigoid has been significantly reduced with the advent of new therapies and treatment modalities. The treatment with systemic and topical corticosteroids forms the mainstay of treatment along with other adjuvant drugs. In the present case study, the use of Prednisolone has proven its efficacy in the extensive disease state of BP and improved the patient’s quality of life.

Bullous Pemphigoid in an Infant: A Case Report

2018 ◽  
Vol 33 (4) ◽  
pp. 448-450 ◽  
Author(s):  
Oscar Thabouillot ◽  
Julien Le Coz ◽  
Nicolas-Charles Roche
Keyword(s):  
Emergency Department ◽  
Differential Diagnosis ◽  
Case Report ◽  
General Practitioner ◽  
Prior Knowledge ◽  
Bullous Pemphigoid ◽  
Skin Disease ◽  
Topical Steroids ◽  
Johnson Syndrome ◽  
Steven Johnson Syndrome

AbstractA seven-month-old girl was referred to the emergency department (ED) after a general practitioner suspected Steven-Johnson syndrome. Actually, the diagnosis of bullous pemphigoid (BP) was made based on biopsies; BP is a rare, autoimmune skin disease involving the presence of blisters known as bullae. The child was efficiently treated with topical steroids. This case shows the importance of the ED physician’s prior knowledge of BP so that a differential diagnosis with other autoimmune diseases (dermatosis, pemphigus) can be made.Thabouillot O, Le Coz J, Roche NC. Bullous pemphigoid in an infant: a case report. Prehosp Disaster Med. 2018;33(4):448–450.

scholarly journals Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

2021 ◽  
Vol 11 ◽  
Author(s):  
S. Morteza Seyed Jafari ◽  
Laurence Feldmeyer ◽  
Simon Bossart ◽  
Dagmar Simon ◽  
Christoph Schlapbach ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Case Report ◽  
Combination Therapy ◽  
Beneficial Effect ◽  
Bullous Pemphigoid ◽  
Skin Disease ◽  
Case Series ◽  
Complete Response ◽  
Preliminary Results ◽  
Alpha Antagonist

Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.

scholarly journals Bullous pemphigoid in 65 years old female: a case report

2019 ◽  
Vol 1 (2) ◽  
Author(s):  
I Dewa Made Rendy Sanjaya ◽  
Putu Artana ◽  
Embun Dini Hari
Keyword(s):  
Case Report ◽  
Bullous Pemphigoid ◽  
Skin Disease ◽  
Autoimmune Disorder ◽  
Good Prognosis ◽  
Topical Steroids ◽  
Current Case ◽  
Chief Complaints ◽  
Intravenous Steroids ◽  
Over Time

Introduction: Bullous pemphigoid is an autoimmune disorder. The incidence of bullous pemphigoid has increased over time, current understanding regarding treatment and complication is an important issue considering the disease often occur in elderly resulting in high rates of morbidity to the patients. Aim of current case report is to describe the clinical relevance regarding symptom and treatment of bullous pemphigoid.Case presentation: A 65 years old female patient, came with chief complaints of bullae in abdominal region with itching and burning sensation in the ruptured bullae. Over time bullae spread in lower and upper extremity. Patient was admitted for four days with therapy intravenous steroids, oral antihistamine, and potent topical steroids. Patient was discharged from hospital in well condition.Conclusion: Bullous pemphigoid is an inflammatory autoimmune skin disease and usually result in good prognosis with adequate management.Keywords: autoimmune, bullous, pemphigoid, skin, disease. 

Abstract #230: Bullous Pemphigoid-Adverse Reaction to Linagliptin (Tradjenta): A Case Report

2015 ◽  
Vol 21 ◽  
pp. 38-39
Author(s):  
Issac Sachmechi ◽  
Raya Galibov ◽  
Venkat Dirish Arukala
Keyword(s):  
Adverse Reaction ◽  
Case Report ◽  
Bullous Pemphigoid

Psoriasis vulgaris accompanied by bullous pemphigoid: A case report.

1988 ◽  
Vol 50 (6) ◽  
pp. 1018-1021 ◽  
Author(s):  
Nobuaki TAKE ◽  
Tetsuya HIRANO ◽  
Osamu IYOTA ◽  
Yoshinori SUENAGA
Keyword(s):  
Case Report ◽  
Bullous Pemphigoid ◽  
Psoriasis Vulgaris

scholarly journals A Case Report of Semaglutide-associated Bullous Pemphigoid

2021 ◽  
Author(s):  
Clayton P. Burruss ◽  
Jordan M. Jones ◽  
Jyoti B. Burruss
Keyword(s):  
Case Report ◽  
Bullous Pemphigoid

scholarly journals Case Report: Rivaroxaban-associated Bullous Pemphigoid in A Patient with Atrial Fibrillation

CJC Open ◽  
2021 ◽  
Author(s):  
Jiaming (Calvin) Liang ◽  
Karanvir Raman ◽  
Siu Him Chan ◽  
A. Yashar Tashakkor
Keyword(s):  
Atrial Fibrillation ◽  
Case Report ◽  
Bullous Pemphigoid

scholarly journals Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient

2021 ◽  
pp. 190-194
Author(s):  
Sineida Berbert Ferreira ◽  
Rachel Berbert Ferreira ◽  
Afonso Cesar Neves Neto ◽  
Silvana Martins Caparroz Assef ◽  
Morton Scheinberg
Keyword(s):  
Case Report ◽  
Skin Disease ◽  
Kinase Inhibitor ◽  
Effective Therapy ◽  
Janus Kinase ◽  
Jak Inhibitor ◽  
Adolescent Patient ◽  
Jak Inhibitors ◽  
Janus Kinase Inhibitor ◽  
History Of

Vitiligo is an autoimmune skin disease presenting with areas of depigmentation. Recent reports suggest that Janus kinase (JAK) inhibitors may be an effective therapy. In this case report, we show our experience with an adolescent patient with a long history of generalized and refractory vitiligo, for which treatment with topical tofacitinib, a JAK inhibitor, associated with phototherapy for 9 months, resulted in near complete repigmentation.

scholarly journals Herpes zoster recurrence within 1 month: A case report

2021 ◽  
Vol 19 ◽  
pp. 205873922110212
Author(s):  
Nan Zhao ◽  
Yulan Geng ◽  
Yexian Li ◽  
Lijuan Liu ◽  
Yanjia Li ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Case Report ◽  
Herpes Zoster ◽  
B Cells ◽  
Varicella Zoster Virus ◽  
Lower Limit ◽  
Skin Disease ◽  
Clinical Manifestations ◽  
Varicella Zoster ◽  
Humoral Immune

Herpes zoster (HZ), caused by the varicella-zoster virus, is an infectious skin disease that rarely recurs after initial presentation. The mechanism underlying HZ recurrence is currently under investigation. In this article, we report a case of HZ relapse within 1 month. Analysis of patient’s clinical manifestations, histopathological features, and flow cytometry results indicated that the absolute and percentage values of B cells were below the lower limit. We hypothesized that the patient had abnormal humoral immune function, which may be one reason leading to the HZ relapse within 1 month. The findings of this case will serve as useful reference for HZ recurrence for clinicians. This case was impactful and added to the literature on HZ recurrence.

Sign in / Sign up

Export Citation Format

Share Document